S8516-S8736-S9125-S9240 Research Study of Genes in Tissue Samples From Patients With B-cell Non-Hodgkin Lymphoma

• Sponsor: Southwest Oncology Group (Other)
• Overall Status: Completed
• CT.gov ID: NCT00985699
• Collaborator: National Cancer Institute (NCI) (NIH)
• Enrollment: 337
• Duration (Months): 62

Study Details

Study Description

Brief Summary

RATIONALE: Studying samples of tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.

PURPOSE: This research study is looking at genes in tissue samples from patients with B-cell non-Hodgkin lymphoma.

Condition or Disease	Intervention/Treatment	Phase
Lymphoma	Genetic: polymorphism analysis; Other: laboratory biomarker analysis; Other: pharmacogenomic studies

Detailed Description

OBJECTIVES:

• To determine if toxicity following treatment for lymphoma varies according to genetic polymorphisms in oxidative stress-related genes (i.e., SOD2, CAT, GPX1, GSTM1, and GSTP1).

• To assess whether these genetic polymorphisms are associated with progression-free survival and/or overall survival in these patients treated for lymphoma.

OUTLINE: Previously collected samples are used for biomarker analysis.

Study Design

• Study Type: Observational
• Actual Enrollment: 337 participants
• Time Perspective: Retrospective
• Official Title: Pharmacogenomics of Oxidative Stress-Related Genes in Lymphoma
• Study Start Date: Apr 1, 2009
• Actual Primary Completion Date: Jun 1, 2014
• Actual Study Completion Date: Jun 1, 2014

Outcome Measures

Primary Outcome Measures

1. Association of polymorphisms in oxidative stress-related genes with overall survival and/or progression-free survival [retrospectively]

2. Association of polymorphisms in these genes with rate of grade 4-5 hematologic toxicity [retrospectively]

Eligibility Criteria

Criteria

• Ages Eligible for Study: 18 Years and Older
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

DISEASE CHARACTERISTICS:

• Diagnosis of aggressive B-cell non-Hodgkin lymphoma

• Previously treated with curative intent using anthracycline-based therapies

• Previously collected paraffin-embedded diagnostic tissues from clinical trials that were collected as part of SWOG treatment protocols (S8516, S8736, S9125, S9240, and S9349) available

PATIENT CHARACTERISTICS:

• Not specified

PRIOR CONCURRENT THERAPY:

• See Disease Characteristics

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

• Southwest Oncology Group
• National Cancer Institute (NCI)

Investigators

• Study Chair: Margaret M. Briehl, PhD, University of Arizona

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

• Responsible Party: Southwest Oncology Group
• ClinicalTrials.gov Identifier: NCT00985699
• Other Study ID Numbers: CDR0000643248; SWOG-S8516-S8736-S9125-S9240-S; U10CA032102
• First Posted: Sep 28, 2009
• Last Update Posted: Jul 24, 2014
• Last Verified: Jul 1, 2014

• Keywords provided by Southwest Oncology Group: non-Hodgkin lymphoma; cutaneous B-cell non-Hodgkin lymphoma; extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue; nodal marginal zone B-cell lymphoma
• Additional relevant MeSH terms: Lymphoma

Study Results

No Results Posted as of Jul 24, 2014